LIFE SCIENCES FORUM 2018
SEPTEMBER 12, METROPOLITAN CLUB, NEW YORK

REGISTRATIONS
registrations@managingip.com
+44 207 779 8938

PROGRAMME
raf.oreilly@legalmediagroup.com

SPONSORSHIP
mpetch@euromoneyplc.com
+44 207 779 8836

WWW.MANAGINGIP.COM/LSF2018
#LIFESCIENCES2018
INTRODUCTION

Recent decisions from the Supreme Court, PTAB and the Federal Circuit threaten to change the landscape for patent prosecution and litigation beyond all recognition. Further, the increasing importance of biologics and the emergence of more and more players in the biosimilars arena, including big pharma and those who are innovators traditionally, has raised the stakes hugely.

The threats are huge, but similarly the opportunities have never been greater, for those who get their patent prosecution, protection and litigation strategies right.

The third annual MIP Life Sciences Forum brings together leading industry players, including in-house and outside counsel, and members of the judiciary, to address the latest decisions and tumultuous changes affecting the life sciences industry today.

By attending, you will be able to benchmark your practices against those of your peers, and understand what you need to do to take advantage of the considerable opportunities available, while at the same time protecting your patents and minimizing your risk.

Book your place today.

BENEFITS OF ATTENDING

Delegates are invited to attend a full day of debates and discussions to hear from, and network with, leading experts in the life sciences industry. All delegates will be party to important debates about the most significant life sciences developments and changes over the past year and on the horizon, with the opportunity to contribute as well as learn. Topics will include:

- Patent prosecution and exclusivity extension - the latest developments, strategies and innovations
- Spotlight on PTAB IPRs - understanding the impact of the Oil States and SAS decisions
- Analysing the latest Hatch-Waxman Act developments
- Pharma litigation: an update on inequitable conduct and other key developments over the past 12 months?
- Litigation management - best practice tips for successful collaborations
- Essential strategies to adopt when commercialising your IP

TO REGISTER, OR FOR MORE INFORMATION PLEASE CALL

KEVIN PRAGAS: +44 207 779 8938
EMAIL: registrations@managingip.com

FOR IN-HOUSE SPEAKING OPPORTUNITIES PLEASE CONTACT

RAF O’REILLY
EMAIL: raf.oreilly@legalmediagroup.com

SPONSORSHIP OPPORTUNITIES

We will create a bespoke solution that will position your organisation as a thought leader and ensure you engage with your target audience. The will help you to meet and influence the people who are going to grow your business. Please contact Melanie Petch on +44 207 779 8836 mpetch@euromoneyplc.com to discuss.
PROGRAMME

8.30 Registration and coffee

9.15 Co-chair’s opening remarks

Elizabeth Weiswasser, co-head, life sciences and patent litigation practices, Weil Gotshal & Manges

Stephanie Donahue, senior director, patent litigation, Sanofi

9.30 Patent prosecution and exclusivity extension – the latest developments, strategies and innovations

• Recent developments on subject matter eligibility in life sciences
• Issues to consider in Patent Term Extension and regulatory exclusivity
• Scope of exclusivity expected in different jurisdictions of significance
• The most challenging exclusivity risks and how to best address them
• Patent prosecution strategies for biosimilars
• Drug label and method of use patent strategies
• Avoiding obviousness-type double patenting
• Unique IP issues emerging from clinical trials

Carla Ji-Eun Kim, director, Sterne Kessler (moderator)

Brian Walsh, assistant general counsel - intellectual property, Bristol Myers Squibb

Joshua Marcus, senior counsel, head of intellectual property, Insmed

John Covert, director, Sterne Kessler

10.20 Morning coffee

10.40 Spotlight on PTAB IPRs – understanding the impact of the Oil States and SAS decisions

• Assessing the impact of Oil States and SAS decisions on IPR proceedings
  o How will the decisions affect pending IPRs as well as completed IPRs?
  o What is the likely practical impact of the Supreme Court’s SAS decision that the PTAB must address all claims challenged in the petition?
  • Will shorter institution PTAB decisions become the standard?
  o What strategies should petitioners and patent owners consider (or reconsider) in light of the Supreme Court’s decisions?
• The latest on the impact of the changes to the claim construction standard at PTAB
• How prevalent are PTAB proceedings for biologic patents currently?

Michael Flibbert, partner, Finnegan Henderson Farabow Garrett & Dunner (moderator)

Honorable Michelle Ankenbrand, lead administrative patent judge, Patent Trial and Appeal Board, USPTO

Kris Lansbery, director, patent attorney, Regeneron Pharmaceuticals

Eren Sommers, partner, Finnegan Henderson Farabow Garrett & Dunner

11.40 Analyzing the latest Hatch-Waxman Act developments

• Filing trends - Lex Machina’s Hatch-Waxman ANDA Litigation 2018 Report revealed a significant increase in the number of ANDA cases filed, the session will consider the reasons for this increase
• Venue - the impact of TC Heartland and recent personal jurisdiction rulings on forum selection and venue challenges in ANDA cases
• Patent Eligibility - Sec.101 considerations in ANDA cases, in view of the Federal Circuit’s recent decisions in Aatrix, Berkheimer, and Vanda
• Views from the trenches on other trends and hot topics in Hatch-Waxman litigation

Robert Rhoad, partner, Dechert (moderator)

Guy Donatiello, senior vice president - intellectual property, Endo Pharmaceuticals

Jonathan Stroud, chief IP counsel, Unified Patents

Rami Bardenstein, director - IP and legal, Glenmark Pharmaceuticals

Jonathan Laeb, partner, Dechert

12.30 Networking lunch

1.30 Pharma litigation: an update on inequitable conduct and other key developments over the past 12 months?

• What are the latest Federal Circuit decisions to be aware of?
• Regeneron v Kymab & Novo Nordisk – what does the recent 2018 UK Court of Appeal decision mean for US life sciences companies operating globally?
• Essential tips on how to avoid inequitable conduct

Robert Counihan, partner, Fenwick & West (moderator)

Serge Ilan-Schneider, director, intellectual property, Par Pharmaceutical

James Trainor, partner, Fenwick & West

2.20 Litigation management – best practice tips for successful collaborations

• Assembling a team—key considerations and best practices
• Best practices for managing outside counsel teams—the in-house perspective
• Protecting the business—strategies for working with the business and legal teams
• Cross-border strategies for managing worldwide patent disputes—best practices for developing and executing a unified strategy

Stephanie Donahue, senior director, patent litigation, Sanofi (moderator)

Elizabeth Weiswasser, co-head, life sciences and patent litigation practices, Weil Gotshal & Manges

Andrew Allen, director, legal counsel Intellectual Property, Dr Reddy’s Laboratories

Larry Coury, executive director of dispute resolution and assistant general counsel, Regeneron Pharmaceuticals

Katelyn O’Reilly, associate, Walsh Pizzi O’Reilly Falanga

3.10 Coffee

3.30 Essential strategies to adopt when commercialising your IP

• Key considerations for early-stage companies in acquiring and commercialising their IP
• Recent decisions impacting transactions in the life sciences space
• Common pitfalls to avoid in license and commercialization agreements

Charan Sandhu, partner, Weil Gotshal & Manges (moderator)

Sesha Kumar GVS, vice president & head of intellectual property - proprietary products, Dr. Reddy’s Laboratories

Aseem Mehta, vice-president, head of patents and licensing law, patents & compliance, Bayer U.S.

Thomas Blankinship, associate director, intellectual property, Mount Sinai Innovation Partners

4.20 Chair’s closing remarks

4.30 Conference ends
1 | Register (Please tick one box)

<table>
<thead>
<tr>
<th>Booking fee</th>
<th>Advisers, consultants, private practice, service providers</th>
<th>In-house IP counsel, R&amp;D managers and heads of legal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early booking rate</td>
<td>☐ $695</td>
<td>☐ FREE</td>
</tr>
<tr>
<td>[before July 13]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard booking rate</td>
<td>☐ $995</td>
<td>☐ FREE</td>
</tr>
<tr>
<td>[after July 13]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL REMITTANCE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2 | Your details for registration (Please print)

Delegation 1

- Name:
- Job title:
- Company:
- Address:
- Postcode:
- Country:
- Tel:
- Email:

Delegation 2

- Name:
- Job title:
- Company:
- Address:
- Postcode:
- Country:
- Tel:
- Email:

3 | Method of payment

Please tick the appropriate box to choose your payment method and sign below:

☐ Bank Transfer (details will be provided by invoice)
☐ Credit Card Payment (pay online at www.managingip.com/LSF2018 or call +44 (0) 207 779 8811)

REGISTRATION: All registrations are subject to final review. Where the registration fee applies, the fee is charged in EUR.

PAYMENT: All registration fees (where applicable) must be received in full prior to the event date or the invoice due date, whichever is sooner.

Please note that in completing this booking form you undertake to adhere to the cancellation and payment terms listed opposite.

Signature: ____________________ Date: ______________

Position: ____________________

To Register

Online
www.managingip.com/LSF2018

Telephone
+44 (0) 20 7779 8938

Email
registrations@managingip.com

Mail
Kevin Pragas
Legal Media Group
8 Bouverie Street
London, EC4Y 8AX, UK

CANCELLATION POLICY: By registering for an event, you are agreeing to the terms and conditions whereby you are liable for the full conference fee (where applicable). All cancellations must be received in writing no later than 6 weeks before the first day of the event (3 August 2018) for a full refund less a 10% administration charge. We cannot accept verbal cancellations. Cancellations received after 3 August 2018 are liable for the full conference fee. However, a substitution can be sent to attend in your place at no extra charge. If owing to a force majeure, Managing IP is obliged to postpone or cancel the event. Managing IP will not be liable for any travel or accommodation expenses incurred by delegates or their organisations. Badge swapping with other registered/non-registered delegates is against our company policy and will not be permitted.

MARKETING PREFERENCES

If you have not previously registered with a Euromoney group website please tick below so that we can keep you updated about Managing IP and other Euromoney group company products and services by:

☐ Email
☐ Telephone
☐ SMS
☐ Mail
☐ Third party (email only)

You can also visit our preference centre and make more specific selections based on your interests. Of course, you can unsubscribe at any time.

If you have previously registered with a Euromoney group website and wish to update your marketing preferences, then please visit our preference centre to do so.

You can view our Privacy Notice and Terms & Conditions of booking.